Ironwood Pharmaceuticals Inc (IRWD): no pain data, skewed side effect profile...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	12
Posts	495
Boards Moderated	0
Alias Born	06/24/2010

chemist99

Re: brownsfan407 post# 233

Thursday, 07/23/2015 9:20:50 PM

Thursday, July 23, 2015 9:20:50 PM

no pain data, skewed side effect profile = no partner IMO.

no partner = slim chance, if any, of competing in the marketplace for a primary care drug with an army of people promoting the first-to-market competitor, IMO.

simple as that.

rant all you want. doesn't change the fact that Phase III CIC data are out - and still no buyout & no partnership despite the "hey we're for sale" press article LOL.

that, and the low (~30%) institutional ownership of SGYP compared with IRWD (~100%), combined with the ~22 mill. short volume for SGYP speak volumes...

"Enter through the narrow gate; for the gate is wide and the way is broad that leads to destruction, and there are many who enter through it. For the gate is small and the way is narrow that leads to life, and there are few who find it.”
Matthew 7:13-1